Yang Zeyuan, Cheung Ramsey C, Jou Janice H, Lim Joseph K, Wong Robert J
Gastroenterology Section, Veterans Affairs Palo Alto Healthcare System, Palo Alto, CA, USA.
Division of Gastroenterology and Hepatology, Stanford University School of Medicine, Palo Alto, CA, USA.
J Clin Exp Hepatol. 2025 Jul-Aug;15(4):102540. doi: 10.1016/j.jceh.2025.102540. Epub 2025 Mar 3.
Previous studies among Korean adults with treatment-naïve chronic hepatitis B (CHB) observed paradoxical relationships between baseline hepatitis B virus (HBV) DNA and risk of hepatocellular carcinoma (HCC). However, these observations have not been validated in Western cohorts. We aim to evaluate the longitudinal risk of cirrhosis or HCC among a national cohort of treatment-naïve patients with noncirrhotic chronic HBV.
Using a national cohort of U.S. Veterans with CHB (with baseline HBV DNA ≥2000 IU/mL) from 1/1/2020 to 3/31/2024, we evaluated the long-term risk of cirrhosis or HCC stratified by baseline high HBV DNA (>6.00 log IU/mL) or moderate HBV DNA (2000-6.00 log IU/mL). We applied propensity score weighting methods to adjust for baseline differences between the two groups.
A total of 1198 noncirrhotic treatment-naïve CHB patients with HBV DNA ≥2000 IU/mL were identified (90.7% were men, 41.7% African American, 29.6% non-Hispanic white, 18.2% Asian, mean age was 54.7 years, 27.9% were HBeAg positive). After propensity score weighting was applied, no significant differences in the incidence of cirrhosis or HCC were observed between CHB patients with moderate vs. high baseline HBV DNA (cirrhosis: 1.02 (95% CI: 0.83-1.25) vs. 1.19 per 100 person-years (95% CI: 0.94-1.51); HR 0.93, 95% CI: 0.68-1.28, = 0.66; HCC: 0.34 (95% CI: 0.24-0.48) vs. 0.29 per 100 person-years (95% CI: 0.18-0.46); HR 1.02, 95% CI: 1.83, = 0.95).
Among a national cohort of Western, predominantly non-Asian patients with treatment-naïve CHB, no significant differences in risk of cirrhosis or HCC were observed by baseline HBV DNA. These data suggest that some epidemiological trends and associations observed in Asian CHB populations may not necessarily be generalizable to non-Asian cohorts with different modes of transmission, risk factors, and virus-specific characteristics.
先前针对初治慢性乙型肝炎(CHB)韩国成年人的研究观察到基线乙型肝炎病毒(HBV)DNA与肝细胞癌(HCC)风险之间存在矛盾关系。然而,这些观察结果尚未在西方队列中得到验证。我们旨在评估全国初治非肝硬化慢性HBV患者队列中肝硬化或HCC的纵向风险。
利用2020年1月1日至2024年3月31日美国退伍军人CHB全国队列(基线HBV DNA≥2000 IU/mL),我们评估了按基线高HBV DNA(>6.00 log IU/mL)或中度HBV DNA(2000 - 6.00 log IU/mL)分层的肝硬化或HCC的长期风险。我们应用倾向评分加权方法来调整两组之间的基线差异。
共识别出1198例基线HBV DNA≥2000 IU/mL的初治非肝硬化CHB患者(90.7%为男性,41.7%为非裔美国人,29.6%为非西班牙裔白人,18.2%为亚洲人,平均年龄54.7岁,27.9%为HBeAg阳性)。应用倾向评分加权后,中度与高基线HBV DNA的CHB患者在肝硬化或HCC发生率上未观察到显著差异(肝硬化:每100人年1.02(95%CI:0.83 - 1.25)对1.19(95%CI:0.94 - 1.51);HR 0.93,95%CI:0.68 - 1.28,P = 0.66;HCC:每100人年0.34(95%CI:0.24 - 0.48)对0.29(95%CI:0.18 - 0.46);HR 1.02,95%CI:0.68 - 1.53,P = 0.95)。
在以西方为主、主要为非亚洲初治CHB患者的全国队列中,按基线HBV DNA未观察到肝硬化或HCC风险的显著差异。这些数据表明,在亚洲CHB人群中观察到的一些流行病学趋势和关联不一定适用于具有不同传播方式、风险因素和病毒特异性特征的非亚洲队列。